Giuliani and Bonetti[5] made a critical assessment of the pharmacological costs of TKIs (erlotinib, gefitinib, afatinib, and osimertinib) in patients with activating EGFR mutations in first-line treatment for advanced NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.